**ANNEX 1**

**Response document for MHRA public consultation on the proposal to make Nuromol Dual Action Pain Relief 200mg/500mg tablets available on General Sale**

**Ref: ARM 100**

**MHRA proposes to permit supply of Nuromol Dual Action Pain Relief 200mg/500mg tablets on general sale outside pharmacies because we consider that the evidence presented in this application demonstrates that the product meets the GSL criterion set out in the legislation.  Your response should address why you agree or disagree with this conclusion and any additional safeguards you consider to be necessary.  We will review all responses received to see if the evidence presented changes our conclusion that the product does meet the GSL criterion.**

**Your details**

**Name:**

**Position (if applicable):**

**Organisation (if applicable):**

**Email:**

|  |
| --- |
| * 1. **Do you consider that Nuromol Dual Action Pain Relief 200mg/500mg tablets meets the criterion for a medicine to be classified as a medicinal product subject to general sale**

Yes 🞏 No 🞏 Not sure 🞏Please provide any comments or evidence to support your response: |

|  |
| --- |
| * 1. **Do you have any specific comments on the leaflet or label provided at Annexes, 2 & 3?**
 |

|  |
| --- |
| * 1. **Do you have any other comments on the reclassification?**
 |

|  |
| --- |
| * 1. **The MHRA may publish consultation responses. Do you want your response to remain confidential?**

Yes 🞏 Partially\* 🞏 No 🞏 \*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete. |

Responses can be continued onto a separate page if required. This form should be returned by email (reclassification@mhra.gov.uk) to arrive by **3 June 2021.** Contributions received after that date cannot be included in the exercise.